Effective October 2, 2009, "ViRexx, a division of Paladin Labs Inc." changed its name to "Paladin Biosciences, a division of Paladin Labs Inc."  All operations remain the same.

On October 20, 2009, Paladin Biosciences received one of three "Grand Challenges" awards for Canada from the Bill & Melinda Gates Foundation for their submission:

Dendritic Cell Receptor - Targeted Malaria Vaccines

Primary Investigator:  Rajan George, Paladin Biosciences, Edmonton, Alberta, Canada - CA

Topic:  Create New Vaccines for Diarrhea, HIV, Malaria, Pneumonia, and TB

Round: Round 3 – October 2009

Rajan George of Paladin Biosciences, a division of Paladin Labs Inc. in Canada will produce a vaccine with multiple malaria antigens to target dendritic cell receptors and without the need for an adjuvant, in an effort to induce both antibody and cell-mediated immune responses to the malaria parasite at various stages of the infection.

Grand Challenges Explorations is a five-year, $100 million initiative to promote innovation in global health.  It is part of the Grand Challenges in Global Health initiative, which is supported by the Gates Foundation to achieve major breakthroughs in global health. 

The Grand Challenges in Global Health initiative is focused on creating breakthroughs to scientific and technological barriers that impede progress in global health. Grand Challenges Explorations is a grant program within the initiative that encourages researchers to explore early-stage, transformational ideas that could change the face of health in the developing world.

For detailed press release, click here.